Innovation, Teoresi acquires HiFuture and focuses on medtech, smart city and industry 4.0

The health market news

Teoresi announces the acquisition of two Milanese companies, HiFuture and BindingFuture, to continue its growth path, particularly in highly strategic areas with a social impact such as technologies for health, connected and sustainable mobility and digitization of industrial processes. The group Theoretical is an international engineering group specialized in frontier technology explains that the two Milanese companies are specialized in technologies for i health marketsmobility and manufacturing such as industry 4.0with applications ranging from medical devices for cancer treatment to cloud solutions for electric micro-mobility.

The acquisition of HiFuture and BindingFuture is part of the rapid growth process of the Group which has led Teoresi, over the last five years, to a strong growth in the volume of revenues (+118%), in the number of employees (+86%) and of the additional 6 offices open internationally. With the two companies, Teoresi is enriched by the skills of over 100 collaborators and 2 new offices in Cologno Monzese (Mi) and Castel Maggiore (Bo). With this acquisition, Teoresi’s skills in software and Artificial Intelligence will thus be enriched with the specialization in the design of hardware and firmware of HiFuture and in cloud applications of BindingFuture for the development of frontier technologies. The two companies become part of the Teoresi Group maintaining their own management, team, offices and strengthening the Group’s technological offer.

“We have identified in HiFuture and BindingFuture two realities that are strongly complementary to Teoresi in terms of technological skills and reference markets” explains Valter Brasso, President and CEO of Teoresi. “The entry of the two companies into the Group allows us to accelerate growth in high-potential markets such as, for example, the biomedical and strengthen the technological offer” adds the CEO.

The development of frontier technologies for innovation in the health field is a mission that unites Teoresi and HiFuture. In particular, Teoresi has turned towards nanotechnologies for precision medicine with the Nanocan project: a new class of devices that use optical fibers integrated into medical needles for the purpose of monitoring tumor markers and releasing drugs. HiFuture collaborates with Cnao, the National Center of Oncological Hadrontherapy in the field of technologies for innovative anticancer therapies such as hadrontherapy, a new type of radiotherapy for the treatment of inoperable tumors based on ions and not on X-rays.

Luigi Zoccolante, CEO of HiFuture, points out that his company “in its evolution and growth path, has reached a dimension, in terms of turnover and personnel, which requires an important organizational and structural evolution in order to continue to guarantee success and growth” and that for this reason “HiFuture has found in Teoresi the ideal partner in terms of size, organization and international presence capable of enhancing its skills and guaranteeing its further development”.

“Discovery, Knowledge and Consolidation were the keywords of these three initial years for BindingFuture” adds Gianni Bonfanti Cto and founder of BindingFuture. “For the new year, the keywords are Development and Organization, and in this – adds Bonfanti – we see Teoresi as a guide we can rely on to achieve the growth objectives we have set ourselves, with a look beyond national borders. The Joining the Group together with HiFuture opens up further possibilities for collaboration and making use of the complementary skills of the three companies”.